Abstract
Morbidity and mortality due to skin cancer is excessively high in renal transplant recipients compared to the general population. This epidemiologic difference is mainly due to the severe immunosuppression that enhances ultraviolet-induced DNA damage and leads to reactivation of potential oncogenic viruses. The most common skin cancer in transplant recipients is squamous cell carcinoma followed by basal cell carcinoma, while in the general population this ratio is reversed. Melanoma and cutaneous lymphoma are relatively rare although they occur more frequently in transplant patients than in the general population. Notably some tumors, such as Kaposi’s sarcoma, are seldom encountered in the general population while they are frequently observed in transplant recipients. Local recurrences and visceral spreading are not so uncommon and pose a major issue for quality of life and overall prognosis of these patients. Timely diagnosis is essential and may be challenging, since the accuracy of clinical diagnosis is modest; thus skin biopsy is an essential tool for appropriate management. In this review, we describe the most common types of skin cancer in renal transplant recipients, with a focus on pathogenic issues that account for the different epidemiology and clinical expression of these neoplasms in this population.
Similar content being viewed by others
References
Stoff B, Salisbury C, Parker D, O’Reilly Zwald F (2010) Dermatopathology of skin cancer in solid organ transplant recipients. Transplant Rev 24(4):172–189
Euvrard S, Kanikatis J, Claudy A (2003) Skin cancer after organ transplantation. N Engl J Med 348:1681–1691
O’Reilly Zwald F, Brown M (2011) Skin cancer in organ transplant recipients: advances in therapy and management. J Am Acad Dermatol 65(2):253–614
Kanitakis J, Euvrard S (2013) Donor-derived skin cancer in a kidney transplant recipient. Nat Rev Nephrol 9:702–703
Rass K, Reichrath J (2008) UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 624:162–178
Sheil AGR (2002) Organ transplantation and malignancy: inevitable linkage. Transplant Proc 34:2436–2437
Hartevelt MM, Bouwes-Bavinck JN, Koote AM et al (1990) Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49:506–509
Ratushny V, Gober MD, Hick R, Ridky TW, Seykora JT (2012) From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 122(2):464–472
Storey A, Thomas M, Kalita A et al (1998) Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature 393:229–234
Zier K, Boulade-Ladame C et al (2012) Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 20:604–617
Gutierrez-Dalmau A, Revuelta I, Ferrer B et al (2010) Distinct immunohistochemical phenotype of non melanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 90:910–986
Andresen PA, Nymoen DA, Kjærheim K, Leivestad T, Helsing P (2013) Susceptibility to cutaneous squamous cell carcinoma in renal transplant recipients associates with genes regulating melanogenesis independent of their role in pigmentation. Biomark Cancer 5:41–47
Wu X, Nguyen BC, Dziunycz P et al (2010) Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 465:368–372
Maluccio M, Sharma V, Lagman M et al (2003) Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 76:597–602
Hojo M, Morimoto T, Maluccio M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530–534
Offman J, Opelz G, Doehler B et al (2004) Defective DNA mismatch repair in acute myeloid leukaemia/myelodysplastic syndrome after organ transplantation. Blood 104:822–828
Ponticelli C (2014) The pros and cons of mTOR inhibitors in kidney transplantation. Expert Rev Clin Immunol 10:295–305
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80(7):883–889
Cowen EW, Nguyen JC, Miller DD et al (2010) Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 62:31–37
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH (2003) A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 63:1727–1730
Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968
Euvrard S, Kanitakis J, Decullier E et al (2006) Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 81:1093–1100
Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA (2006) Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 16:335–339
Ulrich M, Maltusch A, Röwert-Huber J, González S, Sterry W, Stockfleth E et al (2007) Actinic keratoses: non-invasive diagnosis for field cancerization. Br J Dermatol 156:13–17
Reifenberger J, Wolter M, Knobbe CB et al (2005) Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 152:43–51
Ziegler A, Leffell DJ, Kunala S et al (1993) Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 90:4216–4220
Saldanha G, Ghura V, Potter L, Fletcher A (2004) Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 151:157–164
Sexton M, Jones DB, Maloney ME (1990) Histologic pattern analysis of basal cell carcinoma: study pf a series of 1039 consecutive neoplasms. J Am Acad Dermatol 23:1118–1126
Rubin AI, Chen EH, Ratner D (2005) Basal-cell carcinoma. N Engl J Med 353:2262–2269
Lin JS, Eder M, Weinmann S (2011) Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 154:190–201
Seukeran DC, Newstead CG, Cunliffe WJ (1998) The compliance of renal transplant recipients with advice about sun protection measures. Br J Dermatol 138:301–303
Rose RF, Moniem K, Seukeran DC, Stables GI, Newstead CG (2005) Compliance of renal transplant recipients with advice about sun protection measures: completing the audit cycle. Transplant Proc. 37(10):4320–4322
Bahner JD, Bordeaux JS (2013) Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol 31:792–798
Bencini PL, Galimberti MG, Pellacani G, Longo C (2012) Application of photodynamic therapy combined with pre-illumination microneedling in the treatment of actinic keratosis in organ transplant recipients. Br J Dermatol 167(5):1193–1194
Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J (2013) Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 347:f6153
Chen K, Craig JC, Shumack S (2005) Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 152:518–523
Karayannapoulou G, Euvrard S, Kanitakis J (2013) Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients. Anticancer Res 33(9):3711–3714
Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339
Den Akker Hoogendijk-van JM, Harden PN, Hoitsma AJ et al (2013) Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 31:1317–1323
Alter M, Satzger I, Mattern A, Kapp A, Gutzmer R (2013) Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors. Dermatology 227(4):289–294
Sullivan AN, Bryant EA, Mark LA (2012) Malignant melanoma in transplant patients: a case report and review of the literature. Cutis 89(3):133–136
Bilal M, Eason JD, Das K, Sylvestre PB, Dean AG, Vanatta JM (2013) Donor-derived metastatic melanoma in a liver transplant recipient established by DNA fingerprinting. Exp Clin Transplant 11(5):458–463
Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK (2002) Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 12(5):453–463
Russo AE, Torrisi E, Bevelacqua Y et al (2009) Melanoma: molecular pathogenesis and emerging target therapies. Int J Oncol 34(6):1481–1489
Yajima I, Kumasaka MY, Thang ND et al (2012) RAS/RAF/MEK/ERK and PI3 K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2012:354191
Kanitakis J, Baldassini S, Lora V, Euvrard S (2010) BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. Eur J Dermatol 20(2):167–171
Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959
Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961
Le Mire L, Hollowood K, Gray D et al (2006) Melanoma in organ transplant recipients. Br J Dermatol 154:472–477
Sosman JA, Kim KB, Schuchter L et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714
da Rocha Dias S, Salmonson T, van Zwieten-Boot B et al (2013) The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 49(7):1654–1661
Bhatia S, Tykodi SS, Thompson JA (2009) Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 23:488–496
Della Vittoria Scarpati G, Fusciello C, Perri F et al (2014) Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7:203–209
Kainthla R, Kim KB, Falchook GS (2013) Dabrafenib for treatment of BRAF-mutant melanoma. Pharmgenomics Pers Med 7:21–29
Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107–114
Flaherty KT, Infante JR, Daud A et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703
Kadin ME, Hughey LC, Wood GS (2014) Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 70:374–376
Thomas BR, Whittaker S (2012) A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome. Skin Therapy Lett 17:5–9
Seçkin D, Barete S, Euvrard S et al (2013) Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series. Am J Transplant 13:2146–2153
Li JY, Horwitz S, Moskowitz A, Myskowski PL, Pulitzer M, Querfeld C (2012) Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 4:75–89
Jawed SI, wski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol 70:223.e1
Weberschock T, Strametz R, Lorenz M et al (2012) Interventions for mycosis fungoides. Cochrane Database Syst Rev 9:CD008946
Penn I (1999) Kaposi’s sarcoma in transplant recipients. Transplantation 64:669–673
Sarid R, Kelpfish A, Schattner A (2002) Virology, pathogenic mechanisms and associated diseases of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc 77:941–949
Hengge UR, Ruzicka T, Tyring SK et al (2002) Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352
Jham BC, Montaner S (2010) The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor: lessons on dysregulated angiogenesis from a viral oncogene. J Cell Biochem 110:1–9
Dittmer DP, Damania B (2013) Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)–an update. Curr Opin Virol 3(3):238–244
Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ (2008) HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 47(9):1209–1215
Pellet C, Chevret S, Frances C et al (2002) Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in post transplantation Kaposi sarcoma. J Infect Dis 186:110–113
Andreoni M, Goletti D, Pezzotti P et al (2001) Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi’s sarcoma in renal and liver transplant recipients. J Infect 43:195–199
Harwood AR, Osoba D, Hofstader SL et al (1979) Kaposi’s sarcoma in recipients of renal transplants. Am J Med 67(5):759–765
Satter EK (2013) Kaposi sarcoma. Cutis 91(3):120–124
Grayson W, Pantanowitz L (2008) Histologic variants of cutaneous Kaposi sarcoma. Diagn Patol 3:31
Schwartz RA (2004) Kaposi’s sarcoma: an update. J Surg Oncol 87:146–151
Jessop S (2006) HIV-associated Kaposi’s sarcoma. Dermatol Clin 24:509–520
Prinz Vavricka BM, Hofbauer GF, Dummer R et al (2012) Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. Clin Exp Dermatol 37:620–625
Dedicoat M, Vaithilingum M, Newton R (2003) Treatment of Kaposi’s sarcoma in HIV-1 infected individuals with emphasis on resource poor settings. Cochrane Database Syst Rev 3:CD003256
Curatolo P, Quaglino P, Marenco F et al (2012) Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 19:192–198
Duman S, Toz H, Asci G et al (2002) Successful treatment of Kaposi’s sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 17:892–896
Otley CC, Berg D, Ulrich C et al (2006) Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Brit J Dermatol 154:395–400
Campistol JM, Gutierrez-Dalmau A, Torregrosa JV (2004) Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 77:760–762
Stallone G, Schena A, Infante B, Di Paolo S (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352:1317–1323
Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT (2011) Leflunomide with low-dose everolimus for treatment of Kaposi’s sarcoma in a renal allograft recipient. Nephrol Dial Transplant 26:3412–3415
Rockville Merkel Cell Carcinoma Group (2009) Merkel cell carcinoma: recent progress and current priorities on etiology, pathogenesis, and clinical management. J Clin Oncol 27:4021–4026
Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L (2014) Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep 3:46–53
Feng H, Shuda M, Chang Y, Moore PS (2008) Clonal integration of a polyomavirus in human merkel cell carcinoma. Science 319:1096–1100
Bhatia S, Afanasiev O, Nghiem P (2011) Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 13:488–497
Silvestris N, D’Elia F, Tarantino G, Lucarelli A (2000) Merkel cell carcinoma in a renal transplant patient. J Exp Clin Cancer Res 19:399–400
Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Pukkala E, Sihto H, Joensuu H, Kyllönen L (2009) Mäkisalo incidence of merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant 24:3231–3235
Kurnatowska I, Zawiasa A, Narbutt J, Wagrowska-Danielewicz M, Stempien M, Nowicki M (2010) Merkel cell carcinoma in a kidney transplant patient: case report and update on management. Ann Transplant 15:66–70
Friedlaender MM, Rubinger D, Rosenbaum E, Amir G, Siguencia E (2002) Temporary regression of Merkel cell carcinoma metastases after cessation of cyclosporine. Transplantation 73:1849–1850
Acknowledgments
All the authors participated in the preparation of the manuscript. None of them reported any conflict of interest.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ponticelli, C., Cucchiari, D. & Bencini, P. Skin cancer in kidney transplant recipients. J Nephrol 27, 385–394 (2014). https://doi.org/10.1007/s40620-014-0098-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-014-0098-4